Laboratory based study of undetectable thyroid stimulating hormone

M A POLLOCK, A JONES
From the Department of Clinical Biochemistry, Hope Hospital, Salford

SUMMARY The clinical importance of an undetectable thyroid stimulating hormone (TSH) concentration (<0.2 mU/l) was studied in a consecutive series of 2573 requests for routine thyroid function tests. Two hundred and seventeen (8.4%) patients had an undetectable TSH concentration, and of these 39 (18%) had otherwise normal thyroid hormone concentrations and no history of thyroid disease. In a follow up study 71 patients (34 outpatients and 37 inpatients) with undetectable TSH concentration associated with otherwise normal thyroid hormone concentrations were randomly selected during routine reporting of thyroid function test results. None of these patients had a history of thyroid disease. Sex hormone binding globulin concentrations were increased in five out of 50 of these patients and antithyroid antibodies were detectable in four out of 49, suggesting that in most cases the isolated undetectable TSH concentration was not associated with thyroid dysfunction, particularly hyperthyroidism. Isolated undetectable TSH concentration was observed in both inpatients and outpatients and was not associated with any particular clinical condition. Repeat specimens were received in 54 of the 71 patients and TSH concentration remained persistently undetectable in 35 of these.

Sensitive immunometric methods have been developed for measuring the concentration of serum thyroid stimulating hormone (TSH). Many studies using such assays have shown that TSH is suppressed in hyperthyroidism and concentrations are clearly different from those in euthyroid subjects. On the basis of such studies it has been suggested that TSH by sensitive assay is suitable as a first line test of thyroid function. There have been some studies, however, in which undetectable TSH concentrations have been found in patients who did not have hyperthyroidism.

During an analysis of a series of consecutive thyroid function tests sent to this laboratory several patients were observed with undetectable TSH concentrations associated with thyroxine (T₄) and tri-iodothyronine (T₃) concentrations within the reference range. It was decided to identify a group of such patients during routine reporting of results and to request follow up specimens and detailed clinical information.

Sex hormone binding globulin (SHBG) concentration was measured in these patients in an attempt to clarify thyroid state as the concentration of this protein is increased in thyrotoxicosis. Anti-microsomal and antithyroglobulin antibodies were also measured.

Material and methods

TSH was measured routinely by an in-house immunoradiometric assay (IRMA) using two monoclonal antibodies to TSH. Intrabatch coefficient of variation (CV) was <10% at 0.4-59 mU/l with a detection limit of 0.12 mU/l calculated using patient samples with low TSH concentrations, as described by Fraser and Wilde. Interbatch CV was <10% in the concentration range 0.83-16 mU/l. The reference range was 0.5-5.5 mU/l in euthyroid subjects (n = 94). TSH was also measured by the RIAgnost immunoradiometric assay TSH kit in specimens from several patients; the detection limit was 0.03 mU/l as calculated by the method of Fraser and Wilde. The lower limit of the reference range was 0.3 mU/l (n = 94) as determined in the DHSS sponsored evaluation of high sensitivity TSH assay kits. The RIAgnost kit was chosen as it showed the best performance in the DHSS sponsored evaluation.

Serum T₄ and T₃ concentrations were measured by in-house radioimmunoassays and free T₄ by the Amerlex M radioimmunoassay kit (reference ranges: T₄ 50-150 nmol/l; T₃ 1.0-2.9 nmol/l; free T₄ 9-26 pmol/l).
Sex hormone binding globulin concentration was measured by an in-house IRMA (reference ranges: men 15–47 nmol/l; women 24–82 nmol/l). Antimicrosomal and antithyroglobulin antibodies were measured with Wellcome Thymune M and Thymune T haemagglutination assay kits, respectively.

Initially a consecutive series of thyroid function test results on 2573 patients reported from the laboratory were analysed on the basis of the thyroid hormone concentrations and the clinical information given on the request form. In a subsequent study 71 other patients with suppressed TSH concentrations associated with otherwise normal thyroid function tests were randomly identified during routine reporting of results. A follow up specimen, together with detailed clinical information, were requested on these patients.

Results

The prevalence of an undetectable TSH concentration in 2573 thyroid function test results was 8.4% (n = 217). The results were analysed with reference to the clinical information on the request form and the thyroid hormone concentrations (table 1). Ninety three (43%) of the patients with suppressed TSH concentrations had thyrotoxicosis either previously undiagnosed or treated. Sixty three (29%) were receiving thyroid replacement treatment. A further 22 (10%) had raised T4 or raised T3 concentrations. This group had a variety of clinical conditions and may have included patients receiving thyroxine replacement not indicated on the request form. The remaining 39 (18%) of patients had serum T4 and T3 concentrations within the reference range and free T4 concentration was normal in 26 out of 27 of these. Various clinical conditions were again described.

After this initial study 71 other patients with isolated undetectable serum TSH concentrations were randomly identified during routine reporting of the results over a period of one year, and follow up specimens and detailed clinical information were requested. This group included 10 men and 61 women (age range 19–96, median 73). Thirty four were outpatients and 37 inpatients at the time of the original specimen. According to the clinical information received, none of these patients had a history of thyroid disease.

Serum TSH concentration was measured by the RIAgnost IRMA kit in 55 specimens from the group of 71 patients. The RIAgnost kit method (detection limit 0.03 mU/l) is more sensitive than the in-house IRMA method (detection limit 0.12 mU/l). TSH concentrations measured by the RIAgnost method in seven clinically and biochemically thyrotoxic patients were consistently lower than the detection limit of the assay. In the inpatient group 21 out of 28 (75%) had detectable TSH concentrations in the RIAgnost assay (range 0.03–0.21 mU/l), although the concentrations measured were below the lower limit of the reference range for this assay (0.3 mU/l). In the outpatient group TSH was detectable in 20 out of 27 (74%) of the specimens (range 0.03–0.25 mU/l).

SHBG was measured in 50 specimens from the group of 71 patients. In the inpatient group the SHBG concentration was increased in three out of 29 patients and in two out of 21 patients in the outpatient group.

Thyroid antibodies were measured as an additional index of thyroid function in 49 patients. One inpatient had an antimicrosomal (titre >1/100) and antithyroglobulin antibodies present, and three outpatients were positive for antithyroid antibodies.

Fifty four repeat specimens (from 28 outpatients and 26 inpatients) were received two days—59 weeks after the original specimen. The TSH concentration (by in-house IRMA) remained persistently undetectable in 75% of outpatients and 54% of inpatients (table 2). Many different clinical conditions were described in this group, most patients having several concurrent clinical problems.

Discussion

The initial analysis of thyroid function test results

| Table 1 Association of TSH < 0.2 mU/l with clinical condition as defined by information on request form |
|---------------------------------|---------------------------------|
| Clinical condition              | Percentage total |
| Previously undiagnosed thyrotoxic patients | 33 | 15 |
| Treated thyrotoxic patients     | 60 | 28 |
| Patients receiving T4 replacement treatment | 57 | 26 |
| Patients receiving T3 replacement treatment | 5 | 2.3 |
| Hypopituitary patients receiving T4 replacement treatment | 1 | 0.5 |
| Others:                        |                |
| Raised T4 or raised T3         | 22 | 10 |
| T4 and T3 within reference range | 39 | 18 |
| Total                         | 217 | 100 |

<p>| Table 2 Presence of persistently suppressed TSH concentrations in patients with undetectable TSH on initial testing |
|---------------------------------|---------------------------------|---------------------------------|</p>
<table>
<thead>
<tr>
<th>Group</th>
<th>No with persistently suppressed TSH on second measurement</th>
<th>No with measurable TSH on second measurement (range mU/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatients</td>
<td>26</td>
<td>12 (0.23–5.5)</td>
</tr>
<tr>
<td>Outpatients</td>
<td>28</td>
<td>7 (0.2–12)</td>
</tr>
</tbody>
</table>

Pollock, Jones

Laboratory based study of undetectable TSH

suggested that thyrotoxicosis was not the major cause of undetectable serum TSH concentrations in specimens routinely sent to the laboratory. Only 43% of undetectable TSH concentrations were attributable to thyrotoxicosis either previously undiagnosed or treated. A further 29% of suppressed TSH concentrations were found in patients receiving thyroid hormone replacement treatment. Careful analysis of clinical data given is thus needed when interpreting serum TSH concentrations.

A group of 71 other patients having undetectable serum TSH concentrations associated with otherwise normal thyroid hormone concentrations were subsequently identified during routine reporting of results. From the clinical information given none of these patients had a history of thyroid disease nor had been given an iodide load, either in the form of radiographic contrast media or potassium iodide containing ‘cough medicines’. The results of the measurement of SHBG concentration as a marker of peripheral thyroid hormone action suggested that 90% of the patients tested in the group did not have tissue responses typical of hyperthyroidism. Thyroid antibodies were also not detected in 92% of patients tested.

The data thus suggest that the finding of an isolated undetectable TSH concentration was not generally associated with hyperthyroidism in this group of both inpatients and outpatients.

Serum TSH concentration had returned to normal in a number of both outpatients and inpatients by the time that a second specimen was taken, although it remained persistently undetectable in other patients. In all patients thyroid hormone concentrations remained within the reference range. A large percentage of patients in the study was elderly but this may simply reflect the pattern of specimens sent to the laboratory. The current view is also that serum TSH concentration does not change with age in the absence of thyroid disease. Isolated undetectable TSH was not associated with any particular clinical condition.

To establish if the findings of the study were due to limitations in the sensitivity of the in-house TSH IRMA, specimens were also measured in the RIAgnost TSH kit which has a lower detection limit. Using this assay known hyperthyroid patients consistently had undetectable TSH concentrations. In this study 75% of the initial specimens had measurable TSH concentrations in the RIAgnost assay, although the concentrations were still below the lower limit of the reference range for the kit. The use of a more sensitive method for TSH may therefore decrease the number of patients who are classified as having an undetectable TSH concentration suggestive of thyrotoxicosis. Care would still be required in interpreting measurable TSH concentrations below the lower limit of the reference range. This finding is different from that of Spencer et al., who concluded that their finding of patients with undetectable TSH concentrations in an unselected hospital population was not related to method.

Several studies have now suggested that serum TSH may be suppressed in severe illness, particularly in patients receiving treatment with glucocorticoids and dopamine. Spencer et al have shown that in a large series of unselected admissions to an acute medical unit an undetectable serum TSH was three times more likely to be due to non-thyroidal illness than hyperthyroidism.

This study has shown that TSH may also be suppressed in patients who are attending hospital as outpatients but who may have several clinical problems. Undetectable serum TSH associated with T3, T3, and free T4 concentrations within the reference range is not therefore diagnostic of hyperthyroidism in either inpatients or outpatients, a view supported by measurement of other indices of thyroid function, such as detection of antithyroid antibodies and SHBG concentration.

Monoclonal antibodies to TSH were kindly donated by Dr K Siddle, Addenbrooke’s Hospital, Cambridge. We are grateful to the staff of the Endocrine Section, department of clinical biochemistry, Hope Hospital, for performing the routine TSH, T4, T3, and free T4 measurements.

References

Requests for reprints to: Dr M A Pollock, Department of Clinical Biochemistry, Hope Hospital, Eccles Old Road, Salford M6 8HD, England.